摘要
目的研究抗凝血酶Ⅲ(ATⅢ)在肝癌患者和非肝癌患者的活性差异。方法回顾性分析2017年1月至2018年12月治疗肝癌患者95例及非肝癌患者212例,收集各组的临床资料,测量所有患者的ATⅢ活性,比较两组间ATⅢ活性的差异。结果肝癌组ATⅢ活性(U/d L)为73.88+22.03,相对非肝癌组(87.92+19.09),ATⅢ活性低且差异有统计学意义。结论肝癌患者ATⅢ活性低于非肝癌组且差异有统计学意义。对肝癌患者测定ATⅢ活性有一定临床意义。
Objective To investigate the difference in antithrombin Ⅲ(AT Ⅲ) activity between hepatocellular carcinoma(HCC) patients and non-HCC patients. Methods The clinical data, including AT Ⅲactivity, of 95 HCC patients and 212 non-HCC patients, who received treatment during the period from January 2017 and December 2018, were retrospectively analyzed. The AT Ⅲ activity was detemined in all patients. The difference in AT Ⅲ activity between the two groups was evaluated. Results The AT Ⅲ activity in HCC group was(73.88±22.03) IU/dL, which was lower than(87.92±19.09) U/dL in non-HCC group, the difference between the two groups was statistically significant. Conclusion The AT Ⅲ level in HCC patients is significantly lower than that in non-HCC patients, therefore, the determination of AT Ⅲ activity in HCC patients has certain clinical significance.
作者
孔杰
何旭
赵伯翔
公茂峰
陆照璇
周阳逸
陈亮
苏浩波
楼文胜
陈国平
顾建平
王小平
KONG Jie;HE Xu;ZHAO Boxiang;GONG Maofeng;LU Zhaoxuan;ZHOU Yangyi;CHEN Liang;SU Haobo;LOU Wensheng;CHEN Guoping;GU Jianping;WANG Xiaoping(Department of Vascular Interventional Radiology,Affiliated Nanjing Hospital of Nanjing Medical University,Nanjing Municipal First Hospital,Nanjing,Jiangsu Province 210006,China)
出处
《介入放射学杂志》
CSCD
北大核心
2020年第12期1232-1234,共3页
Journal of Interventional Radiology
关键词
肝癌
抗凝血酶Ⅲ
抗凝
hepatocellular carcinoma
antithrombinⅢ
anticoagulation